BRKR vs DHR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BRKR and DHR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BRKR and DHR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.

Full BRKR guide

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BRKR drivers: High-end instruments moat; Adjacent growth vectors.
• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. For DHR, valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s), leaving little room for disappointment.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BRKR if you believe its drivers more; DHR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BRKR and DHR guides.

BRKR. Bruker beat reduced Q1 2026 expectations (non-GAAP EPS of ~$0.31 versus a ~$0.23 consensus) even as organic revenue fell, and it reaffirmed full-year guidance. The forward earnings multiple of roughly 15x to 16x reflects the market weighing a quality niche franchise against near-term research-spending softness.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, while adjusted EPS grew faster on margins and buybacks. The stock has typically carried a premium valuation, with a trailing P/E in the mid-30s to mid-40s and a forward P/E closer to the low 20s as estimates rise. Figures are approximate and as of JULY 2026.

Headline figures (approximate, July 2026): BRKR shows revenue (ttm) ~$3.46B, q1 2026 revenue ~$823M (+2.7% YoY, -4.4% organic), fy2026 revenue guidance ~$3.57B to $3.60B, fy2026 non-gaap eps guidance ~$2.10 to $2.15; DHR shows revenue (fy2025) ~$24.6B, adj. diluted eps (fy2025) ~$7.80, free cash flow (fy2025) ~$5.3B, 2026 adj. eps guidance ~$8.35 to $8.55.

BRKR and DHR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BRKR and DHR exposure against your real portfolio. It is not an investment adviser.